CEO: | Jeremy Skillington |
CFO: | Ian O’Connel |
Executive Chairman: | Cathal Friel |
Independent Non-Executive Director: | Brendan Buckley |
Independent Non-Executive Director: | Edward Gibson |
Independent Non-Executive Director: | Luke O’Neill |
Non-Executive Dir: |
Address: | Queen Mary Bioenterprises Innovation Centre, 42 New Road, London, United Kingdom, E1 2AX |
Phone: | +44 (0)20 7183 1499 |
Website: | http://www.poolbegpharma.com/ |
Sector: | Pharma and Biotech(LSE) |
Index: | FTSE AIM All-Share |
ISIN: | GB00BKPG7Z60 |
Currency | UK Pounds |
Share Price | 10.60p |
Change Today | 0.25p |
% Change | 2.42 % |
52 Week High | 11.50 |
52 Week Low | 6.55 |
Volume | 1,368,085 |
Shares Issued | 500.00m |
Market Cap | £53.00m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:24 | 130,000 @ 10.50p |
16:21 | 40,682 @ 10.50p |
15:56 | 1,968 @ 10.50p |
15:54 | 30,000 @ 10.60p |
15:36 | 234 @ 10.67p |
CEO | Jeremy Skillington |
CFO | Ian O’Connel |
You are here: research